Glaucoma is probably not useful as a red flag for amyloidosis

Oscar Westina The Heart Center, University Hospital of Copenhagen, Rigshospitalet, DenmarkCorrespondence[email protected]
View further author information

Jawad H. Butta The Heart Center, University Hospital of Copenhagen, Rigshospitalet, DenmarkView further author information

Steffen Heegaardb Department of Ophthalmology, University Hospital of Copenhagen, Rigshospitalet, Denmark

Emil L. Fosbøla The Heart Center, University Hospital of Copenhagen, Rigshospitalet, DenmarkView further author information

Finn Gustafssona The Heart Center, University Hospital of Copenhagen, Rigshospitalet, DenmarkView further author information

References

Seca M, Ferreira N, Coelho T. Vitreous amyloidosis as the presenting symptom of familial amyloid polyneuropathy TTR Val30Met in a portuguese patient. Case Rep Ophthalmol. 2014;5(1):92–97.
PubMedGoogle Scholar
Reynolds MM, Veverka KK, Gertz MA, et al. Ocular manifestations of familial transthyretin amyloidosis. Am J Ophthalmol. 2017;183:156–162.
PubMed Web of Science ®Google Scholar
Ando E, Ando Y, Okamura R, et al. Ocular manifestations of familial amyloidotic polyneuropathy type I: long term follow up. Br J Ophthalmol. 1997;81(4):295–298.
PubMed Web of Science ®Google Scholar
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–1568.
PubMed Web of Science ®Google Scholar
Kakihara S, Hirano T, Imai A, et al. Small gauge vitrectomy for vitreous amyloidosis and subsequent management of secondary glaucoma in patients with hereditary transthyretin amyloidosis. Sci Rep. 2020;10(1):5574.
PubMed Web of Science ®Google Scholar